Detail akcie Implantica SDR-A online

Business Summary: Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Implantica AG revenues increased 3% to EUR1.5M. Net loss decreased 22% to EUR12.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Medical products and implants segment loss decrease of 28% to EUR13.1M. Basic Earnings per Share excluding Extraordinary Items remained flat at -EUR0.01.